Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: Relationship to changes in muscarinic receptor levels

Neuropsychopharmacology

Volumn 30, Issue 6, 2005, Pages 1076-1087

  Laplante, François ^a,b   Nakagawasai, Osamu ^a   Srivastava, Lalit K ^a   Quirion, Rémi ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Animal model; Biperiden; Oxotremorine; Prepulse inhibition of the acoustic startle; Receptor autoradiography; Schizophrenia

Indexed keywords

BIPERIDEN; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; N [2 [2 (DIPROPYLAMINOMETHYL) 1 PIPERIDYL]ETHYL] 5,11 DIHYDRO 6 OXO 6H PYRIDO[2,3 B][1,4]BENZODIAZEPINE 11 CARBOXAMIDE; OXOTREMORINE; PIRENZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; AUDITORY SYSTEM; BEHAVIOR; BINDING SITE; BODY TEMPERATURE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; DRUG RECEPTOR BINDING; HIPPOCAMPUS; LIGAND BINDING; MALE; NEWBORN; NONHUMAN; NUCLEUS ACCUMBENS; PAIN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SALIVATION; TREMOR;

ANALGESICS; ANIMALS; ANIMALS, NEWBORN; AUTORADIOGRAPHY; BEHAVIOR, ANIMAL; BODY TEMPERATURE; FEMALE; HIPPOCAMPUS; HYPOTHERMIA; MALE; MUSCARINIC AGONISTS; OXOTREMORINE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; REACTION TIME; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC; SALIVATION; STARTLE REACTION; TREMOR;

EID: 19344370156     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300640     Document Type: Article

References (80)

1. Becker A, Grecksch G, Bernstein HG, Hollt V, Bogerts B (1999). Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology (Berl) 144: 333-338.
2. Bernstein HG, Grecksch G, Becker A, Hollt V, Bogerts B (1999). Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport 10: 2307-2311.
3. Berntson GG, Hart S, Ruland S, Sarter M (1996). A central cholinergic link in the cardiovascular effects of the benzodiazepine receptor partial inverse agonist FG 7142. Behav Brain Res 74: 91-103.
4. Bolden C, Cusack B, Richelson E (1991). Clozapine is a potent and selective muscarinic antagonist at the five cloned human muscarinic acetylcholine receptors expressed in CHO-K1 cells. Eur J Pharmacol 192: 205-206.
5. Brake WG, Flores G, Francis D, Meaney MJ, Srivastava LK, Gratton A (2000). Enhanced nucleus accumbens dopamine and plasma corticosterone stress responses in adult rats with neonatal excitotoxic lesions to the medial prefrontal cortex. Neuroscience 96: 687-695.
6. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC et al (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14: 87-96.
7. Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE et al (2003). Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci 17: 1403-1410.
8. Callicott JH (2003). An expanded role for functional neuroimaging in schizophrenia. Curr Opin Neurobiol 13: 256-260.
9. Caulfield MP (1993). Muscarinic receptors - characterization, coupling and function. Pharmacol Ther 58: 319-379.
10. Chiba T, Kayahara T, Nakano K (2001). Efferent projections of infralimbic and prelimbic areas of the medial prefrontal cortex in the Japanese monkey, Macaca fuscata. Brain Res 888: 83-101.
11. Connor JD, Rossi GV, Baker WW (1966a). Analysis of the tremor induced by injection of cholinergic agents into the caudate nucleus. Int J Neuropharmacol 5: 207-216.
12. Connor JD, Rossi GV, Baker WW (1966b). Characteristics of tremor in cats following injections of carbachol into the caudate nucleus. Exp Neurol 14: 371-382.
13. 3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64: 1761-1771.
14. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000). Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48: 381-388.
15. Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2001). Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: a study of Brodmann's areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158: 918-925.
16. Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL (1996). The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1: 54-58.
17. Dilsaver SC, Alessi NE (1988). Temperature as a dependent variable in the study of cholinergic mechanisms. Prog Neuropsychopharmacol Biol Psychiatry 12: 1-32.
18. Duttaroy A, Gomeza J, Gan JW, Siddiqui N, Basile AS, Harman WD et al (2002). Evaluation of muscarinic agonist-induced analgesia in muscarinic acetylcholine receptor knockout mice. Mol Pharmacol 62: 1084-1093.
19. Dworkin RH (1994). Pain insensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophr Bull 20: 235-248.
20. Eltze M, Figala V (1988). Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes. Eur J Pharmacol 158: 11-19.
21. Everitt BJ, Robbins TW (1997). Central cholinergic systems and cognition. Annu Rev Psychol 48: 649-684.
22. Flores G, Barbeau D, Quirion R, Srivastava LK (1996). Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. J Neurosci 16: 2020-2026.
23. Gainetdinov RR, Bohn LM, Walker JK, Laporte SA, Macrae AD, Caron MG et al (1999). Muscarinic supersensitivity and impaired receptor desensitization in G protein-coupled receptor kinase 5-deficient mice. Neuron 24: 1029-1036.
24. Gomeza J, Shannon H, Kostenis E, Felder C, Zhang L, Brodkin J et al (1999). Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci USA 96: 1692-1697.
25. Grecksch G, Bernstein HG, Becker A, Hollt V, Bogerts B (1999). Disruption of latent inhibition in rats with postnatal hippocampal lesions. Neuropsychopharmacology 20: 525-532.
26. Hamilton SE, Loose MD, Qi M, Levey AI, Hille B, McKnight GS et al (1997). Disruption of the ml receptor gene ablates muscarinic receptor-dependent M current regulation and seizure activity in mice. Proc Natl Acad Sci USA 94: 13311-13316.
27. Hardy SG (1985). Analgesia elicited by prefrontal stimulation. Brain Res 339: 281-284.
28. Hardy SG, Haigler HJ (1985). Prefrontal influences upon the midbrain: a possible route for pain modulation. Brain Res 339: 285-293.
29. Hart S, Sarter M, Berntson GG (1999). Cholinergic inputs to the rat medial prefrontal cortex mediate potentiation of the cardiovascular defensive response by the anxiogenic benzodiazephine receptor partial inverse agonist FG 7142. Neuroscience 94: 1029-1038.
30. Harte SE, Hoot MR, Borszcz GS (2004). Involvement of the intralaminar parafascicular nucleus in muscarinic-induced antinociception in rats. Brain Res 1019: 152-161.
31. Hyde TM, Crook JM (2001). Cholinergic systems and schizophrenia: primary pathology or epiphenomena? J Chem Neuroanat 22: 53-63.
32. Iwamoto ET, Marion L (1993). Characterization of the antinociception produced by intrathecally administered muscarinic agonists in rats. J Pharmacol Exp Ther 266: 329-338.
33. Jones CK, Shannon HE (2000). Muscarinic cholinergic modulation of prepulse inhibition of the acoustic startle reflex. J Pharmacol Exp Ther 294: 1017-1023.
34. Klarner A, Koch M, Schnitzler HU (1998). Induction of Fos-protein in the forebrain and disruption of sensorimotor gating following N-methyl-D-aspartate infusion into the ventral hippocampus of the rat. Neuroscience 84: 443-452.
35. Koch M (1996). The septohippocampal system is involved in prepulse inhibition of the acoustic startle response in rats. Behav Neurosci 110: 468-477.
36. Kraepelin E (1919). Dementia Praecox and Paraphrenia. E&S Livingstone: Edinburgh.
37. Laplante F, Srivastava LK, Quirion R (2004a). Alterations in dopaminergic modulation of prefrontal cortical acetylcholine release in post-pubertal rats with neonatal ventral hippocampal lesions. J Neurochem 89: 314-323.
38. Laplante F, Stevenson CW, Gratton A, Srivastava LK, Quirion R (2004b). Effects of neonatal ventral hippocampal lesion in rats on stress-induced acetylcholine release in the prefrontal cortex. J Neurochem 91: 1473-1482.
39. Lautenbacher S, Krieg JC (1994). Pain perception in psychiatric disorders: a review of the literature. J Psychiatr Res 28: 109-122.
40. Le Pen G, Grottick AJ, Higgins GA, Martin JR, Jenck F, Moreau JL (2000). Spatial and associative learning deficits induced by neonatal excitotoxic hippocampal damage in rats: further evaluation of an animal model of schizophrenia. Behav Pharmacol 11: 257-268.
41. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL (2003). Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol Psychiatry 54: 1162-1170.
42. Lipska BK, Al Amin HA, Weinberger DR (1998). Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage. Neuropsychopharmacology 19: 451-464.
43. Lipska BK, Aultman JM, Verma A, Weinberger DR, Moghaddam B (2002). Neonatal damage of the ventral hippocampus impairs working memory in the rat. Neuropsychopharmacology 27: 47-54.
44. Lipska BK, Jaskiw GE, Weinberger DR (1993). Post-pubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 9: 67-75.
45. Lipska BK, Swerdlow NR, Geyer MA, Jaskiw GE, Braff DL, Weinberger DR (1995). Neonatal excitotoxic hippocampal damage in rats causes post-pubertal changes in prepulse inhibition of startle and its disruption by apomorphine. Psychopharmacology (Berl) 122: 35-43.
46. Lipska BK, Weinberger DR (2000). To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23: 223-239.
47. Marcotte ER, Pearson DM, Srivastava LK (2001). Animal models of schizophrenia: a critical review. J Psychiatry Neurosci 26: 395-410.
48. Matsui M, Motomura D, Karasawa H, Fujikawa T, Jiang J, Komiya Y et al (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci USA 97: 9579-9584.
49. Myers RD (1980). Handbook of the Hypothalamus. Marcel Dekker: New York. pp 83-210.
50. Neafsey EJ (1990). Prefrontal cortical control of the autonomic nervous system: anatomical and physiological observations. Prog Brain Res 85: 147-165.
51. O'Donnell P, Lewis BL, Weinberger DR, Lipska BK (2002). Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cereb Cortex 12: 975-982.
52. Overstreet DH, Miller CS, Janowsky DS, Russell RW (1996). Potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. Toxicology 111: 119-134.
53. Paxinos G, Watson C (1982). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
54. Quirion R, Hammer Jr RP, Herkenham M, Pert CB (1981). Phencyclidine (angel dust)/sigma 'opiate' receptor: visualization by tritium-sensitive film. Proc Natl Acad Sci USA 78: 5881-5885.
55. Quirion R, Wilson A, Rowe W, Aubert I, Richard J, Doods H et al (1995). Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired. J Neurosci 15: 1455-1462.
56. Raedler TJ, Knable MB, Jones DW, Urbina RA, Gorey JG, Lee KS et al (2003). In vivo determination of muscarinic acetylcholine receptor availability in schizophrenia. Am J Psychiatry 160: 118-127.
57. Roldan G, Bolanos-Badillo E, Gonzalez-Sanchez H, Quirarte GL, Prado-Alcala RA (1997). Selective M1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats. Neurosci Lett 230: 93-96.
58. Rowe WB, O'Donnell JP, Pearson D, Rose GM, Meaney MJ, Quirion R (2003). Long-term effects of BIBN-99, a selective muscarinic M2 receptor antagonist, on improving spatial memory performance in aged cognitively impaired rats. Behav Brain Res 145: 171-178.
59. Sams-Dodd F, Lipska BK, Weinberger DR (1997). Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology (Berl) 132: 303-310.
60. Sanchez C, Meier E (1993). Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice. Pharmacol Toxicol 72: 262-267.
61. Sarter M (1994). Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? Psychopharmacology (Berl) 114: 539-550.
62. Sarter M, Bruno JP (1997). Cognitive functions of cortical acetylcholine: toward a unifying hypothesis. Brain Res Brain Res Rev 23: 28-46.
63. Sarter M, Bruno JP (1999). Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders. Trends Neurosci 22: 67-74.
64. Schroeder H, Grecksch G, Becker A, Bogerts B, Hoellt V (1999). Alterations of the dopaminergic and glutamatergic neurotransmission in adult rats with postnatal ibotenic acid hippocampal lesion. Psychopharmacology (Berl) 145: 61-66.
65. Shiloh R, Weizman A, Epstein Y, Rosenberg SL, Valevski A, Dorfman-Etrog P et al (2001). Abnormal thermoregulation in drug-free male schizophrenia patients. Eur Neuropsychopharmacol 11: 285-288.
66. Spreekmeester E, Rochford J (2000). Selective mu and delta, but not kappa, opiate receptor antagonists inhibit the habituation of novelty-induced hypoalgesia in the rat. Psychopharmacology (Berl) 148: 99-105.
67. Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB et al (2001). The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299: 782-792.
68. Takeuchi J, Fulton J, Jia ZP, Abramov-Newerly W, Jamot L, Sud M et al (2002). Increased drinking in mutant mice with truncated M5 muscarinic receptor genes. Pharmacol Biochem Behav 72: 117-123.
69. Tandon R (1999). Cholinergic aspects of schizophrenia. Br J Psychiatry 174(Suppl 37): 7-11.
70. Tandon R, Greden JF, Haskett RF (1993). Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls. Schizophr Res 9: 19-23.
71. Tandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson JA (1991). Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr Res 4: 23-30.
72. Van Den Buuse M (2003). Acute effects of antipsychotic drugs on cardiovascular responses to stress. Eur J Pharmacol 464: 55-62.
73. Van Eden CG, Buijs RM (2000). Functional neuroanatomy of the prefrontal cortex: autonomic interactions. Prog Brain Res 126: 49-62.
74. Vaucher E, Fluit P, Chishti MA, Westaway D, Mount HT, Kar S (2002). Object recognition memory and cholinergic parameters in mice expressing human presenilin 1 transgenes. Exp Neurol 175: 398-406.
75. Vertes RP (2004). Differential projections of the infralimbic and prelimbic cortex in the rat. Synapse 51: 32-58.
76. Wall PM, Flinn J, Messier C (2001). Infralimbic muscarinic M1 receptors modulate anxiety-like behaviour and spontaneous working memory in mice. Psychopharmacology (Berl) 155: 58-68.
77. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al (2001). Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 50: 825-844.
78. Wess J (2004). Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Annu Rev Pharmacol Toxicol 44: 423-450.
79. Wu MF, Jenden DJ, Fairchild MD, Siegel JM (1993). Cholinergic mechanisms in startle and prepulse inhibition: effects of the false cholinergic precursor N-aminodeanol. Behav Neurosci 107: 306-316.
80. Yang CR, Seamans JK, Gorelova N (1999). Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21: 161-194.